Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.59 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.59 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.59 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.59 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.59 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | REN | P00797 | 7/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9282508 | 1.00 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL892964 | 0.89 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7173287 | 0.89 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8532202 | 0.88 | KLK5 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6445261 | 0.88 | KLK5 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6445320 | 0.88 | KLK5 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6444857 | 0.88 | KLK5 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8534875 | 0.88 | KLK5 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9848360 | 0.88 | KLK5 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7270592 | 0.88 | KLK5 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | claimed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | claimed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040192780-A1 | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2004-09-30 | — | — | US | disclosed |
| US-20040087801-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2004-05-06 | — | — | US | disclosed |
| US-20030236201-A1 | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2003-12-25 | — | — | US | disclosed |
| US-6515025-B2 | Renin inhibitor | PHARMACIA CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-20020115867-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | HANSON GUNNAR J (US) | 2002-08-22 | — | — | US | disclosed |
| US-6403648-B2 | RENIN INHIBITOR | G. D. SEARLE & CO. | 2002-06-11 | — | — | US | disclosed |
| US-20020025934-A1 | Ethynyl alanine amino diol compounds for treatment of hypertension | G.D. SEARLE & CO. (US) | 2002-02-28 | — | — | US | disclosed |
| WO-1990000050-A1 | AMINOALKYLAMINOCARBONYL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| WO-1990000051-A1 | ETHEREAL N-TERMINAL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| EP-0349922-A2 | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0349921-A2 | Etheral n-terminal aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | disclosed |
| US-4877785-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1989-10-31 | — | — | US | disclosed |
| EP-0310072-A2 | Non-peptidyl beta-succinamidoacyl aminodiols as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0310071-A2 | Non-peptidyl alpha-aminoacyl aminodiol carbamates as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0310070-A2 | Alpha-aminoacyl beta-aminoacyl aminodiols as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0310073-A2 | Non-peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087801-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | REN, AGTR1, AGTR2 | PSEN1 4807/4885PSEN2 4834/4885APH1B 3432/4885 |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | PSEN1 5/4885PSEN2 6/4885APH1B 12/4885 |
| US-20020025934-A1 | Ethynyl alanine amino diol compounds for treatment of hypertension | REN, AGTR1, AGT | PSEN1 4371/4885PSEN2 4504/4885APH1B 4043/4885 |
| US-20030236201-A1 | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | REN, AGTR1, AGTR2 | PSEN1 4752/4885PSEN2 4775/4885APH1B 3405/4885 |
| US-20020115867-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | REN, AGT, AGTR1 | PSEN1 4864/4885PSEN2 4851/4885APH1B 3782/4885 |
| US-20040192780-A1 | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | REN, AGTR1, AGTR2 | PSEN1 4752/4885PSEN2 4775/4885APH1B 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.